A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD®

Vaccine

Volumn 28, Issue 30, 2010, Pages 4719-4730

  Bonanni, Paolo ^a   Cohet, Catherine ^b   Kjaer, Susanne K ^c,d   Latham, Nina B ^b   Lambert, Paul Henri ^e   Reisinger, Keith ^f   Haupt, Richard M ^g  

^a UNIVERSITY OF FLORENCE   (Italy)

^b SANOFI PASTEUR   (France)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f Primary Physicians Research   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

Author keywords

HPV vaccine; Monitoring; Post licensure

Indexed keywords

PLACEBO; WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18;

AUSTRALIA; AUTOIMMUNE DISEASE; CANADA; CANCER SCREENING; CHILD CARE; CLINICAL TRIAL; DATA BASE; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EUROPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOGENICITY; INCIDENCE; LICENSING; LONG TERM CARE; MANAGED CARE ORGANIZATION; MORBIDITY; POPULATION RESEARCH; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; VACCINATION; VACCINE PRODUCTION; VERRUCA VULGARIS; ADOLESCENT; ADULT; CHILD; CLINICAL TRIAL (TOPIC); CONDYLOMATA ACUMINATA; DRUG INDUSTRY; FEMALE; FRANCE; HEALTH INSURANCE; HEALTH PERSONNEL ATTITUDE; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; PATIENT ATTITUDE; POSTMARKETING SURVEILLANCE; REGISTER; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

ADOLESCENT; ADULT; ATTITUDE OF HEALTH PERSONNEL; CHILD; CLINICAL TRIALS AS TOPIC; CONDYLOMATA ACUMINATA; DRUG INDUSTRY; EUROPE; FEMALE; FRANCE; HUMANS; LICENSURE; MANAGED CARE PROGRAMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; PRODUCT SURVEILLANCE, POSTMARKETING; REGISTRIES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 77954217554     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.04.070     Document Type: Review

References (35)

1. Markowitz L.E., Dunne E.F., Saraiya M., Lawson H.W., Chesson H., Unger E.R. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007, 56(RR-2):1-24.
2. World Health Organization. Meeting of the Immunization Strategic Advisory Group of Experts, November 2008 - conclusions and recommendations. 9-1-2009. Weekly Epidemiological Report No. 1-2, 2009, 84, 1-16. Available at [cited June 2, 2009]. https://www%20who%20int/wer/2009/wer8401_02%20pdf%202009.
3. Centers for Disease Control and Prevention. Human papillomavirus (HPV) vaccine post-licensure monitoring and implementation activities centers for disease control and prevention. Available at http://www%20cdc%20gov/std/hpv/HPV-monitoring-plan-10-06-2008%20pdf%202009.
4. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356(19):1915-1927. The FUTURE II Study Group.
5. Dias D., Van Doren J., Schlottmann S., Kelly S., Puchalski D., Ruiz W., et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomavirus 6, 11, 16 and 18. Clin Diagn Lab Immunol 2005, 12(8):959-969.
6. International patent numbers WO 2003/019143 A2, WO 2006/116276 A2 and WO 2006/116303 A2. Available at http://www%20wipo%20int/portal/index%20html%20en%202008.
7. Greer C.E., Wheeler C.M., Manos M.M. Sample preparation and PCR amplification from paraffin-embedded tissues. PCR Methods Appl 1994, 3(6):S113-S122.
8. Kjaer S.K., Tran T.N., Sparen P., Tryggvadottir L., Munk C., Dasbach E., et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 nordic countries. J Infect Dis 2007, 196(10):1447-1454.
9. Reisinger K.S., Block S.L., Lazcano-Ponce E., Samakoses R., Esser M.T., Erick J., et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007, 26(3):201-209.
10. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356(19):1928-1943.
11. Giuliano A, Palefsky J. 2008 European Research Organization on Genital Infection and Neoplasia (EUROGIN) International Multidisciplinary Conference. " Efficacy of quadrivalent HPV (types 6/11/16/18) vaccine in reducing the incidence of HPV-related genital disease in young men." [cited July 12, 2009]. Available at http://www%20eurogin%20com/2008/EUROGIN2008_LastMinuteAbstracts%20pdf%202008.
12. Block S.L., Brown D.R., Chatterjee A., Gold M.A., Sings H.L., Meibohm A., et al. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine. Pediatr Infect Dis J 2009.
13. Merck & Co., Inc. The Pregnancy Registry for GARDASIL [cited July 12, 2009]. Available at http://www%20merckpregnancyregistries%20com/gardasil%20html%202009.
14. Lehman H.P., Benson J.O., Beninger P.R., Anderson C.A., Blumenthal S.J., Sharrar R.G. A five-year evaluation of reports of overdose with indinavir sulfate. Pharmacoepidemiol Drug Saf 2003, 12(6):449-457.
15. Centers for Disease Control and Prevention. Metropolitan Atlanta Congenital Defects Program. Surveillance procedure manual and guide to computerized anomaly record. Atlanta, GA. Centers for Disease Control and Prevention 1998.
16. Centers for Disease Control and Prevention. Birth defects and genetic diseases branch 6-digit code for reportable congenital anomalies, Atlanta, GA, version 08/07. Available at Accessed February 2, 2009. Centers for Disease Control and Prevention - MMWR Morbidity and Mortality Weekly Report 2009. http://www.cdc.gov/ncbddd/BD/documents/MACDPcode.pdf.
17. Lilienfeld D.E., Stolley P.D. Foundations of epidemiology 1994, Oxford Press, New York. third ed.
18. Dana A., Buchanan K.M., Goss M.A., Seminack M.M., Shields K.E., Korn S., et al. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol 2009, 114(6):1170-1178.
19. Munoz N., Manalastas R., Pitisuttihum P., Tresukosol D., Monsonego J., Ault K., et al. Safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women between 24 and 45 years of age: a randomized, double-blind trial. Lancet 2009, 373:1921-1922.
20. Martcheva M., Bolker B.M., Holt R.D. Vaccine-induced pathogen strain replacement: what are the mechanisms?. J R Soc Interface 2008, 5(18):3-13.
21. Capra G., Giovannelli L., Bellavia C., Migliore M.C., Caleca M.P., Perino A., et al. HPV genotype prevalence in cytologically abnormal cervical samples from women living in south Italy. Virus Res 2008, 133(2):195-200.
22. Belgian Cancer Registry. Annual statistics since 1999: 2003-F-BEL-Lft [online]. Available from URL: Belgian Cancer Registry Annual statistics since 1999: 2003-F-BEL-Lft [online] Available from URL: [Accessed February 4, 2010]. http://www%20registreducancer%20org/.
23. De Vuyst H., Clifford G., Li N., Franceschi S. HPV infection in Europe. Eur J Cancer 2009, 45(15):2632-2639.
24. Siegrist C.A., Lewis E.M., Eskola J., Evans S.J., Black S.B. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J 2007, 26(11):979-984.
25. Fender M., Schott J., Baldauf J.J., Muller J., Schlund E., Dellenbach P. EVE, a regional campaign for the screening of cervical cancer. Organization, 7-years results and perspectives. Presse Med 2003, 32(33):1545-1551.
26. Fender M., Schott J., Baldauf J.J., Muller J., Schlund E., Dellenbach P. Membres du bureau de l'Association EVE. [EVE, a regional campaign for the screening ofcervical cancer. Organization, 7-years results and perspectives]. Presse Med. 2003, 32(33):1545-1551.
27. Fender M., Schaffer P., Dellenbach P. Can we and must we organize cervical cancer screening in France? Results of the pilot project " EVE" in the department of Bas-Rhin. J Gynecol Obstet Biol Reprod (Paris) 1998, 27(7):683-691.
28. Dahlstrom L.A., Tran T.N., Lundholm C., Young C., Sundstrom K., Sparen P. Attitudes to HPV vaccination among parents of children aged 12-15 years-a population-based survey in Sweden. Int J Cancer 2010, 126(2):500-507.
29. Fairley C.K., Hocking J.S., Gurrin L.C., Chen M.Y., Donovan B., Bradshaw C.S. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009, 85(7):499-502.
30. Public Health Agency of Canada, Statement on human papillomavirus vaccine. An Advisory Committee Statement (ACS). Can Commun Dis Rep 2007;33(ACS-2):1-31.
31. Flaherty JM. The Budget Plan 2007. Aspite to a stronger, safer, better Canada. [cited August 19, 2009]. http://www%20budget%20gc%20ca/2007/pdf/speeche%20pdf%20March%2019,%202007.
32. Colucci R, Hryniuk W, Savage C. Report card on cancer in Canada, 2008. HPV vaccination programs in Canada: are we hitting the mark? [cited August 19, 2009]. http://www%20canceradvocacy%20ca/reportcard/2008/reportcard-2008%20pdf%202009.
33. Marra F., Ogilvie G., Colley L., Kliewer E., Marra C.A. Epidemiology and costs associated with genital warts in Canada. Sex Transm Infect 2009, 85(2):111-115.
34. Kliewer E.V., Demers A.A., Elliott L., Lotocki R., Butler J.R., Brisson M. Twenty-year trends in the incidence and prevalence of diagnosed anogenital warts in Canada. Sex Transm Dis 2009, 36(6):380-386.
35. Howlett R.I., Miller A.B., Pasut G., Mai V. Defining a strategy to evaluate cervical cancer prevention and early detection in the era of HPV vaccination. Prev Med 2009, 48(5):432-437.